Cargando…
SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model
Autores principales: | Wiewel, Maryse A, van der Meer, Anne Jan, Haddad, Jonathan, Jacobson, Eric W, Vlasuk, George P, van der Poll, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953342/ http://dx.doi.org/10.1186/cc12909 |
Ejemplares similares
-
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
por: Krueger, James G., et al.
Publicado: (2015) -
Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers
por: Venkatasubramanian, Sowmya, et al.
Publicado: (2013) -
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers
por: Libri, Vincenzo, et al.
Publicado: (2012) -
SRT2183 and SRT1720, but not Resveratrol, Inhibit Osteoclast Formation and Resorption in the Presence or Absence of Sirt1
por: Thiyagarajan, Ramkumar, et al.
Publicado: (2023) -
The influence of corticosteroids on the release of novel biomarkers in human endotoxemia
por: de Kruif, Martijn D., et al.
Publicado: (2007)